Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oriflame in relation to the groups change of domicile from Luxembourg to Switzerland
Mandate

Vinge advises Oriflame in relation to the groups change of domicile from Luxembourg to Switzerland

May 11, 2015

Vinge advises Oriflame in connection with the process of changing the group’s domicile from Luxembourg to Switzerland. As part of this process, Oriflame Holding AG, a wholly owned Swiss subsidiary of Oriflame Cosmetics S.A., has announced a share-for-share exchange transaction. The shares of Oriflame Holding are intended to be listed on the main market of Nasdaq Stockholm.

Erik Sjöman and Dain Hård Nevonen (partners, capital markets & public M&A) and Sabina Börjesson and Joel Wahlberg advise Oriflame. Mattias Schömer (partner, tax) and Tora Hansjons provide tax advice.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026